p53 protein as a prognostic indicator in breast carcinoma: A comparison of four antibodies for immunohistochemistry

British Journal of Cancer

Volumn 73, Issue 1, 1996, Pages 29-35

  Horne, G M ^a   Anderson, J J ^a   Tiniakos, D G ^a   McIntosh, G G ^a   Thomas, M D ^a   Angus, B ^a   Henry, J A ^a   Lennard, T W J ^a   Horne, C H W ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Breast carcinoma; Immunohistochemistry; p53; Tumour suppressor gene

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C JUN; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030029626     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.6     Document Type: Article

References (49)

1. ALLDRED DC, CLARK GM, ELLEDGE R, FUQUA SAW, BROWN RW, CHAMNESS GC, OSBORNE CK AND McGUIRE WL. (1993). Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node negative breast cancer. J. Natl Cancer Inst., 85, 200-206.
2. ANDERSON JJ, TINIAKOS D, HORNE G, MELLON K, ANGUS B AND HORNE CHW. (1994). Production and characterization of retinoblastoma gene product specific monoclonal antibodies for use on formalin-fixed, paraffin-embedded tissues. J. Pathol., 172 suppl. 135A.
3. BAAS IO, MULDER J-W. OFFERHAUS GJA, VOGELSTEIN B AND HAMILTON SR. (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 172, 5-12.
4. BAKER SJ, FEARON ER, NIGRO JM, HAMILTON SR, PREISINGER AC, JESSUP JM, VANTUINEN P, LEDBETTER DH, BARKER DF, NAKAMURA V, WHITE R AND VOGELSTEIN B. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 244, 217-221.
5. BANKS L, MATLASHEWSKI G AND CRAWFORD L. (1986). Isolation of human p53 specific monoclonal antibodies and their use in the study of human p53 expression. Eur. J. Biochem., 159, 529-534.
6. BARBARESCHI M, LEONARDI E, MAURI FA, SERIO G AND PALMA PD. (1992), p53 and c-erbB-2 expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am. J. Clin. Pathol., 98, 408-418.
7. BARNES DM. (1989). Breast cancer and a proto-oncogene. c-erbB-2 is a reliable prognostic marker. Br. Med. J., 299, 1061.
8. BARNES DM, DUBLIN EA, FISHER CJ, LEVISON DA AND MILLIS RR. (1993). Immunohistochemical detection of p53 protein in mammary carcinoma. Hum. Pathol., 24, 469-476.
9. BÁRTEK J. BÁRTKOVÁ J, VOIJESEK B, STASKOVA Z, LUKAS J, REJTHAR A, KOVARIK J, MIDGLEY CA, GANNON JV AND LANE DP. (1991). Aberrant expression of the p53 onco-protein is a common feature of a wide spectrum of human malignancies. Oncogene. 6, 1699-1703.
10. BARTEK J. BÁRTKOVÁ J, LUKÁS J. STASKOVÁ Z, VOJTESEK B AND LANE DP. (1993). Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J. Pathol., 169, 27-34.
11. CATTORETTI G, RILKE F, ANDEROLA S, DAMATO L AND DELIA D. (1988). p53 expression in breast cancer. Int. J. Cancer, 41, 178-183.
12. CORBETT IP, HENRY JA, ANGUS B, WATCHORN CJ, WILKINSON L, HENNESSEY C, GULICK WJ, TUZI NL, MAY FEB, WESTLEY BR AND HORNE CHW. (1990). NCL-CBII, a new monoclonal antibody recognising the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-lixed, paraffin-embedded tissues. J. Pathol., 161, 15-25.
13. EARLY BREAST CANCER TRIALISTS COLLABORATIVE GROUP. (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 339, 1-15, 71-85.
14. ELLEDGE RM, FUQUA SAW, CLARK GM, PUJOL P, ALLRED G AND McGUIRE WL. (1993). Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res. Treat., 26, 225-235.
15. ELSTON CW AND ELLIS IO. (1991). The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat., 22, 207-219.
16. HALL PA AND LANE DP. (1994), p53 in tumour pathology: can we trust immunohistochemistry? Revisited! J. Pathol., 172, 1-4.
17. HENRY JA, PIGGOTT NH, MALLICK UK, NICHOLSON S, FARNDON JJ, WESTLEY BR AND MAY FEB. (1991). pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br. J. Cancer, 63, 615-622.
18. HENRY L, ANGUS B, LENNARD TWJ. (1993). New monocloncal antibodies to oestrogen and progesterone receptor: characterization and clinical studies in human breast cancer. J. Pathol., 169 suppl, 168A.
19. IWAYA K, TSUDA H, HIRAIDE H, TAMAKI K, TAKAMURA S, FUKUTOMI T, MUKAI K AND HIROHASHI S. (1991). Nuclear p53 immunoreaction associated with poor prognosis of breast ccancer. Jpn. J. Cancer Res., 82, 835-840.
20. JACQUIEMER J, MOLÈS JP, PENAULT-LLORCA F, ADÉLAIDE J, TORRENTE M, VIENS P, BIRNBAUM D AND THEILLET C. (1994). p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br. J. Cancer, 69, 846-852.
21. KERN SE, PIETENPOL JA, THAINGALINGHAM S, SEYMOUR A, KINXLER KW AND VOGELSTEIN B. (1992). Oncogenic form of p53 inhibit p53-regulated gene expression. Science, 256, 827-830.
22. LANE DP. (1992). p53, guardian of the genome. Nature, 358, 15-16.
23. LANE DP AND BENCHIMAL S. (1990). p53 oncogene or anti-oncogene? Gene Dev., 4, 1-8.
24. LAMBKIN HA, MOTHERSILL CM AND KELEHAN P. (1994). Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J. Pathol., 172, 13-18.
25. LEVINE AJ, MOMAND J AND FINLAY CA. (1991). The p53 tumour-suppressor gene. Nature, 351, 453-456.
26. McINTOSH GG, ANDERSON JJ, MILTON I, STEWARD M, PARR AH, THOMAS MD, HENRY JA, ANGUS B AND HORNE CHW. (1995). Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene, 11, 885-891.
27. MACKAY J, STEEL CM, ELDER DA, FOREST APM AND EVANS HJ. (1988). Allele loss on short arm of chromosome 17 in breast cancers. Lancet, 2, 1384-1385.
28. MARTINAZZI M, CRIVELLI F, ZAMPATTI C AND MARTINAZZI S. (1993). Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am. J. Clin. Pathol., 100, 213-217.
29. MULLIGAN LM, MATLASHEWSKI GJ, SCRABLE HJ AND CAVENEE WK. (1990). Mechanisms of p53 loss on human sarcomas. Proc. Natl Acad. Sci. USA, 87, 5863-5867.
30. NEVILLE AM. (1990). Are breast cancer axillary node mcirometastases worth detecting (editorial). J. Pathol., 161, 283-284.
31. OSTROWSKI JL, SAWAN A, HENRY L, WRIGHT C, HENNESSEY RA, LENNARD TJW, ANGUS B AND HORNE CHW. (1991). p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J. Pathol., 164, 75-81.
32. PICKSLEY SM, VOJTESEK B, SPARKS A AND LANE D. (1994). Immunochemical analysis of the interaction of p53 with mdm2; Fine mapping of the mdm2 binding site on p53 using synthetic peptides. Oncogene, 9, 2523-2529.
33. POLLER DN, HUTCHINGS CE, CALEA M, BEEL JA, NICHOLSON RA, ELSTON CW, BLAMEY RW AND ELLIS IO. (1992). p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor. c-erbB-2 protein overexpression, and oestrogen receptor. Br. J. Cancer, 66, 583-588.
34. PIGGOTT NH, HENRY JA, MAY FEB AND WESTLEY BR. (1991). Anti-peptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry. J. Pathol., 163, 95-104.
35. SAWAN A, RANDALL B, ANGUS B, WRIGHT C, HENRY JA, OSTROWSKI J, HENNESSEY C, LENNARD TJW, CORBETT I AND HORNE CHW. (1992). Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J. Pathol., 168, 23-28.
36. SAWAN A, LASCU I, VERON M, ANDERSON JJ, WRIGHT C, HORNE CHW AND ANGUS B. (1994). nm23/NDPK expression human breast cancer in relation to relapse, survival and other prognostic factors: an immunohistochemical study. J. Pathol., 172, 27-34.
37. SHI SR, KEY ME AND KARLA KL. (1991). Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39, 741-748.
38. SPANDAU DF. (1994). Distinct conformations of p53 are observed at different stages of keratinocyte differentiation. Oncogene, 9, 1861-1868.
39. SPANDIDOS DA, KARIOSSIFIDI H, MALLIRI A, LINDARDOPOULOS S, VASSILARIOS S, TSIKKINIS A AND FEILD JK. (1992). Expression of ras, Rb1 and p53 proteins in human breast cancer. Anticancer Res., 12, 81-90.
40. STEPHEN CW, HEIMINEN P AND LANE DP. (1995). Characterization of epitopes on human p53 using phage displayed peptide libraries: Insights into antibody peptide interactions. J. Mol. Biol., 248, 58-78.
41. THOMAS MD, PARR A, McINTOSH GG, ANDERSON JJ, ELLIS I, NICHOLSON R, HORNE CHW AND ANGUS BA. (1995). Measurement of p53 protein in human breast cancer: comparison between immunohistochemistry and semi-quantitative ELISA values. J. Pathol., 176 suppl, 172.
42. TINIAKOS D, SCOTT L, CORBETT IP, PIGGOTT NH AND HORNE CHW. (1994). Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4. J. Pathol., 172, 19-26.
43. TRUDEL M, MULLIGAN L, CAVERNEE W, MARGOLESE R, COTE J AND GARIEPY G. (1992). Retinoblastoma and p53 gene product expression in breast carcinoma. Hum. Pathol., 23, 1388-1394.
44. VARLEY JM, BRAMMAR WJ, LANE DP, SWALLOW JE, DOLAN C AND WALKER RA. (1991). Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene, 6, 413-421.
45. VOGELSTEIN B AND KINZLER KW. (1992). p53 function and dysfunction. Cell, 70, 523-526.
46. VOJTESEK B, BÁRTEK J, MIDGLEY CA AND LANE DP. (1992). An immunochemical analysis of the human-nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 151, 237-244.
47. WALKER RA, DEARING SJ, LANE DP AND VARLEY JM. (1991). Expression of p53 protein in infiltrating and in-situ breast carcinomas. J. pathol., 165, 203-211.
48. XU L, CHEN Y-T, HUVOS AG, ZLOTOLOW IM, RETTIG WJ, OLD LJ AND GARIN-CHESA P. (1994). Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagm. Mol. Pathol., 3, 83-92.
49. YAMASHITA H, KOBAYASHI S, IWASE E, ITOH Y, KUZUSHIMA T, IWATA H. ITOH K, HAITO A, YAMASHITA T, MASAOKA A ANDKIMURA N. (1993). Analysis of oncogenes and tumour suppressor genes in human breast cancer. Jpn. J. Cancer Res., 84, 871-878.